Loading...

ELEV ELEVATION ONCOLOGY INC Business Restructuring 8-K Filing

LVTN

LV

ELEVATION ONCOLOGY INC

(ELEV)

2025 8-K

Show Summary

Show Summary

Merger of Equals

Financial Statements

Debt-Equity Swaps

Loan Prepayment

Management Change

Corporate Restructuring

Nasdaq Compliance

Financial Results

Management Change

Clinical Trial Updates

Q3 Financial Results

Nasdaq Compliance Notice

Financial Results and Clini...

Annual Meeting Voting Results

Earnings Report

Resignation and Appointment

Financial Results Announcement

Compliance with Nasdaq List...

Appointment of Director

Program Updates and Milestones

Earnings Report

Clinical Trial Initiation

Financial Results Announcement

Annual Meeting Approval

Agreement for Stock Issuance

Clinical Data Announcement

Financial Results Announcement

Financial Results Announcement

Amendment to Bylaws

Financial Results, CEO Resi...

External Links:

On March 20, 2025, Elevation Oncology announced it will stop developing EO-3021 due to a 22.2% response rate in trials, while continuing with EO-1022 and reducing its workforce by about 70%, expecting to have $93.2 million to fund operations into lat

AI Assistant

ELEVATION ONCOLOGY INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.